B-cell depletion became a mainstay of multiple sclerosis treatment, where infusion time and dosing convenience increasingly drive product choice. Briumvi (ublituximab) competes primarily on those terms.
Glycoengineered for enhanced antibody-dependent cytotoxicity, it achieves effective B-cell depletion at lower doses, allowing one-hour maintenance infusions twice a year. The intravenous anti-CD20 antibody treats relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Briumvi entered a market led by established anti-CD20 agents, positioning itself on shorter infusion time and price. As a biologic with no biosimilar competition, its uptake depends largely on infusion-center throughput economics and payer preference.
